Transcatheter aortic valve implantation (TAVI) is a new technique with the potential for transforming the treatment of high-risk patients with aortic stenosis. Expansion and refinement of transcatheter approaches for aortic valve implantation is an area of active research and development. While a variety of transcatheter valves are currently in the pipeline, the Edwards Sapien and Medtronic CoreValve represent the two currently established devices in Europe, and both have been reported to have excellent flow characteristics.
Cardionovum has announced that it expects to launch in Europe, in the fourth quarter of 2012, its Prolimus Biograde, a next-generation sirolimus-eluting coronary stent system, which is designed to optimise long-term patient results.
Arterial Remodeling Technologies (ART) has reported the successful first-in-human implantation of its novel biodegradable stent. The case is part of the ARTDIVA (Arterial remodeling transient dismantling vascular angioplasty) clinical trial.
Cumulative radiation exposure to both patients and operators has become a topic of great interest given the overall increased use of both cardiovascular and non-cardiovascular imaging modalities. This is all the more important with the increasing usage of multimodality imaging, including non-invasive (single-photon emission computed tomography, computed tomography angiography) and invasive procedures in patients with known or suspected coronary artery disease.
With its 10-year anniversary and exceeding 50,000 implantations worldwide, transcatheter aortic valve implantation (TAVI) has proven to be a viable and safe treatment strategy for patients with severe aortic stenosis and high operative risk. However, with the prospect of treating younger or less sick patients, a number of vexing issues remain.
Abbott has announced its financial results for the second quarter ended June 30, 2012. Reported sales increased 2.0 percent, including an unfavourable 4.7 percent effect of foreign exchange
Canadian company CellAegis Devices, Inc., has announced that it has received a CE Mark for its autoRIC™ Device, which the company says for the first time allows simple, consistent, reliable and cost-effective automation of remote ischemic conditioning (RIC) at the point of care
Sexual dysfunction may be a marker of cardiovascular disease in men with longstanding type 1 diabetes, investigators announced at the 72nd Scientific Sessions of the American Diabetes Association (ADA).
Women with severe aortic stenosis appear to derive more benefit from transcatheter aortic valve implantation (TAVI) than their male counterparts, researchers found.
For patients with symptomatic severe aortic stenosis who are at high risk for surgical complications, both transcatheter aortic valve implantation (TAVI) and surgical replacement dramatically improve health status within 1 year, an analysis of the PARTNER trial showed.
Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollment in a global, multicenter, randomized clinical trial comparing the Medtronic CoreValve® System with surgical aortic valve replacement in patients with severe aortic stenosis who are at intermediate risk to undergo open-heart surgery. The trial, called Medtronic CoreValve Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, will evaluate the potential for the minimally-invasive CoreValve System to be considered for less-sick patients who typically are treated with open-heart surgical aortic valve replacement (SAVR) today.
AstraZeneca (NYSE: AZN) today announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America.1 PAD patients are at high risk of myocardial infarction (MI), strokes, and other health complications. EUCLID is designed to evaluate cardiovascular (CV) event rate and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.
The risk of major events following stenting of a blocked left main coronary artery is about the same as seen with bypass surgery initially, but more subsequent procedures may be needed, an all-comers registry showed.
The US Food and Drug Administration (FDA) has given clearance to TriReme Medical for an expanded matrix of sizes for its Glider PTCA balloon catheter. Glider is now approved for the treatment of lesions in the coronary vasculature in balloon diameters from 1.5 – 3.5mm and in lengths from 4mm to 20mm.
La Sociedad Española de Medicina Interna (SEMI) ha elaborado un Protocolo de uso de dabigatrán etexilato en la Fibrilación Auricular (FA), con el fin de asegurar un manejo correcto del nuevo anticoagulante oral y de formar al colectivo de médicos internistas en esta novedad sobre anticoagulación en la FA.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos